AUA 2017: Late-Breaking abstract- A phase III blinded study of immediate post-TURBT instillation of gemcitabine versus saline in patients with newly diagnosed or occasionally recurring Grade I/II non-muscle invasive bladder cancer: SWOG S0337
Boston, MA (UroToday.com) This is a phase III blinded study investigating the impact of immediate postoperative instillation of gemcitabine on preventing recurrence after resection of low grade non-muscle invasive bladder cancers. Gemcitabine, dosed 2g/100cc saline, was instilled immediately after TURBT and held within the bladder for 1 hour. The control patients received 100cc of saline within the bladder. A total of 406 patients were randomized. Of these, 13 had T2 disease, while 86 had high grade tumor. Randomization resulted in similar clinicopathologic characteristics between the treatment and control arms. No severe toxicity was observed in the treatment group. On the final analysis, a 34% reduction in recurrence was observed in the intention to treat group, while an even higher 47% reduction was observed in the target population with low grade, non-muscle invasive group. Subset analysis showed no difference in patients with high grade cancer. While the reduction in recurrence was similar as has been shown with immediate postoperative mitomycin instillation, gemcitabine is regarded as safer in this setting.
Presenter: Edward Messing, MD
Written By: Roger Li MD Urologic Oncology Fellow, UT MD Anderson Cancer Center @UrogerliMD
Ashish M. Kamat MD Wayne B. Duddlesten Professor, UT MD Anderson Cancer Center
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA